Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,683 | $1,381 | $6 | $5 |
| G&A Expenses | $1,975 | $2,024 | $652 | $320 |
| SG&A Expenses | $1,975 | $2,024 | $652 | $320 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $3,657 | $3,405 | $658 | $325 |
| Operating Income | -$3,657 | -$3,405 | -$658 | -$325 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $318 | $379 | $12,819 | $27 |
| Pre-Tax Income | -$3,339 | -$3,026 | $12,161 | -$299 |
| Tax Expense | $0 | $0 | $55 | $0 |
| Net Income | -$3,339 | -$3,026 | $12,106 | -$299 |
| % Margin | – | – | – | – |
| EPS | -0.019 | -0.02 | 0.033 | -0.001 |
| % Growth | 3% | -161.5% | 2,600% | – |
| EPS Diluted | -0.019 | -0.018 | 0.03 | -0.001 |
| Weighted Avg Shares Out | 172,263 | 151,314 | 366,184 | 376,248 |
| Weighted Avg Shares Out Dil | 172,263 | 171,950 | 367,777 | 376,248 |
| Supplemental Information | – | – | – | – |
| Interest Income | $318 | $379 | $0 | $0 |
| Interest Expense | $0 | $0 | $23 | $15 |
| Depreciation & Amortization | $3,657 | $3,405 | $658 | $325 |
| EBITDA | $318 | $379 | -$0 | -$325 |
| % Margin | – | – | – | – |